Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ-61178104, a Novel Tumor Necrosis Factor-Alpha and Interleukin-17A Bispecific Antibody, in Healthy Subjects.

Akpalu DE, Frederick B, Nnane IP, Yao Z, Shen F, Ort T, Fink D, Dogmanits S, Raible D, Sharma A, Xu Z.

J Clin Pharmacol. 2019 Jul;59(7):968-978. doi: 10.1002/jcph.1393. Epub 2019 Feb 18.

PMID:
30776134
2.

Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.

Nnane IP, Han C, Jiao Q, Tam SH, Davis HM, Xu Z.

Basic Clin Pharmacol Toxicol. 2017 Jul;121(1):13-21. doi: 10.1111/bcpt.12761. Epub 2017 Mar 8.

3.

Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study.

Hirschfield GM, Gershwin ME, Strauss R, Mayo MJ, Levy C, Zou B, Johanns J, Nnane IP, Dasgupta B, Li K, Selmi C, Marschall HU, Jones D, Lindor K; PURIFI Study Group.

Hepatology. 2016 Jul;64(1):189-99. doi: 10.1002/hep.28359. Epub 2016 Jan 14.

PMID:
26597786
4.

CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.

Raghu G, Martinez FJ, Brown KK, Costabel U, Cottin V, Wells AU, Lancaster L, Gibson KF, Haddad T, Agarwal P, Mack M, Dasgupta B, Nnane IP, Flavin SK, Barnathan ES.

Eur Respir J. 2015 Dec;46(6):1740-50. doi: 10.1183/13993003.01558-2014. Epub 2015 Oct 22.

5.

Pharmacokinetics and Safety of Single Intravenous Doses of JNJ-54452840, an Anti-β1-Adrenergic Receptor Antibody Cyclopeptide, in Healthy Male Japanese and Caucasian Participants.

Nnane IP, Plotnikov AH, Peters G, Johnson M, Kojak C, Vutikullird A, Ariyawansa J, De Vries R, Davies BE.

Clin Pharmacokinet. 2016 Feb;55(2):225-36. doi: 10.1007/s40262-015-0309-8.

PMID:
26242382
6.

Unexpected Toxicology Findings in Rats Dosed With an Antihuman IL-13 Monoclonal Antibody.

Martin PL, Nnane IP, Branigan P, Louden C.

Int J Toxicol. 2015 Sep-Oct;34(5):393-407. doi: 10.1177/1091581815591840. Epub 2015 Jun 29.

PMID:
26124191
7.

Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody.

Nnane IP, Xu Z, Zhou H, Davis HM.

Basic Clin Pharmacol Toxicol. 2015 Oct;117(4):219-25. doi: 10.1111/bcpt.12391. Epub 2015 Mar 5.

8.

Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.

van Hartingsveldt B, Nnane IP, Bouman-Thio E, Loza MJ, Piantone A, Davis HM, Petty KJ.

Br J Clin Pharmacol. 2013 May;75(5):1289-98. doi: 10.1111/j.1365-2125.2012.04477.x.

9.

Biotransformation of letrozole in rat liver microsomes: effects of gender and tamoxifen.

Tao X, Piao H, Canney DJ, Borenstein MR, Nnane IP.

J Pharm Biomed Anal. 2007 Feb 19;43(3):1078-85. Epub 2006 Oct 12.

PMID:
17045772
10.

The effect of tamoxifen on the pharmacokinetics of letrozole in female rats.

Tao X, Brodie AM, Nnane IP.

Biopharm Drug Dispos. 2006 Oct;27(7):335-44.

PMID:
16912967
11.

Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model.

Handratta VD, Jelovac D, Long BJ, Kataria R, Nnane IP, Njar VC, Brodie AM.

J Steroid Biochem Mol Biol. 2004 Oct;92(3):155-65.

PMID:
15555909
13.
14.
16.

Pharmacokinetics of novel inhibitors of androgen synthesis after intravenous administration in mice.

Nnane IP, Njar VC, Brodie AM.

Cancer Chemother Pharmacol. 2003 Jun;51(6):519-24. Epub 2003 Apr 25.

PMID:
12715204
18.

Pharmacokinetics of trimethylamine in rats, including the effects of a synthetic diet.

Nnane IP, Damani LA.

Xenobiotica. 2001 Oct;31(10):749-55.

PMID:
11695853
20.
21.

Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.

Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ, Brodie AM.

Cancer Res. 2000 Dec 1;60(23):6630-40.

22.

Potent inhibition of retinoic acid metabolism enzyme(s) by novel azolyl retinoids.

Njar VC, Nnane IP, Brodie AM.

Bioorg Med Chem Lett. 2000 Sep 4;10(17):1905-8.

PMID:
10987414
23.
24.

Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo.

Nnane IP, Njar VC, Liu Y, Lu Q, Brodie AM.

J Steroid Biochem Mol Biol. 1999 Dec 15;71(3-4):145-52.

PMID:
10659703
25.

Metabolism of ethyl methyl sulphide and sulphoxide in rat microsomal fractions.

Nnane IP, Damani LA.

Xenobiotica. 1999 Nov;29(11):1101-13.

PMID:
10598745
26.

Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.

Grigoryev DN, Long BJ, Nnane IP, Njar VC, Liu Y, Brodie AM.

Br J Cancer. 1999 Oct;81(4):622-30.

27.

Pharmacokinetics of 2-methoxyphenylmetyrapone and 2-bromophenylmetyrapone in rats.

Nnane IP, Tsai MC, Lin G, Damani LA, Mitterhauser M, Zolle I.

Eur J Drug Metab Pharmacokinet. 1999 Jan-Mar;24(1):23-9.

PMID:
10412888
28.
29.

Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds.

Nnane IP, Kato K, Liu Y, Long BJ, Lu Q, Wang X, Ling YZ, Brodie A.

Endocrinology. 1999 Jun;140(6):2891-7.

PMID:
10342882
30.

High performance liquid chromatographic analysis of a novel aminoalkylpyridine anticonvulsant 2-(4-chlorophenyl)amino-2-(4-pyridyl)ethane.

Lin G, Nnane IP, Damani LA, Tse KK, Chow AH, Kadaba PK.

J Pharm Biomed Anal. 1998 Nov;18(3):403-9.

PMID:
10096834
31.
32.
33.
34.

The assessment of flavin-containing monooxygenase activity in intact animals.

Damani LA, Nnane IP.

Drug Metabol Drug Interact. 1996;13(1):1-28. Review.

PMID:
8902428

Supplemental Content

Loading ...
Support Center